CHICAGO--(BUSINESS WIRE)--Ventas, Inc. (NYSE: VTR) (“Ventas” or the “Company”) today reported results for the third quarter ended September 30, 2026.


CEO Remarks
“Ventas delivered strong enterprise results and growth in the third quarter, as we executed our 1-2-3 strategy and drove outperformance at scale. Our large and growing Senior Housing Operating Portfolio (“SHOP”) powered the Company’s organic property growth, and we used our differentiated platform, operating expertise and data advantages to generate results that significantly outperformed industry benchmarks,” said Debra A. Cafaro, Ventas Chairman and CEO.
“Additionally, we are aggressively expanding our SHOP business through attractive acquisitions designed to increase our enterprise growth and enhance the Company’s multiyear growth outlook. We have closed over $5 billion of investments focused on U.S. senior housing year to date. We have significant momentum in the market, and we are currently advancing our robust pipeline of actionable SHOP investment opportunities.
“With our commitment to helping people live longer, healthier and happier lives, we are well positioned to serve the secular demand from a wave of Baby Boomers turning 80 over the coming decade.
“We are again raising our full year earnings guidance primarily because of our 2026 investment activity. Our business and team are built to meet this moment, and we are focused on creating value for stakeholders,” Cafaro concluded.
Third Quarter and Other 2026 Highlights
*Some of the financial measures throughout this press release are non-GAAP measures. Refer to the Non-GAAP Financial Measures Reconciliation tables at the end of this press release for additional information and a reconciliation to the most directly comparable GAAP measure.
Third Quarter 2026 Company Results
For the Third Quarter 2026, reported per share results were:
|
| Quarter Ended September 30, | ||||||
|
| 2026 |
| 2025 |
| $ Change |
| % Change |
Attributable Net Income |
| $0.13 |
| $0.14 |
| $(0.01) |
| (7%) |
Nareit FFO* |
| $1.01 |
| $0.88 |
| $0.13 |
| 15% |
Normalized FFO* |
| $0.99 |
| $0.90 |
| $0.09 |
| 10% |
SHOP Growth
In the third quarter, SHOP Same-Store Cash NOI increased 16% year-over-year. Same-Store revenue per occupied room (“RevPOR”) grew 5% and average occupancy grew 290 basis points year-over-year. Same-Store Cash NOI margin* grew 190 basis points year-over-year, benefitting from favorable operating leverage combined with RevPOR and occupancy growth.
During the third quarter, U.S. SHOP Same-Store Cash NOI increased 17%, and average occupancy grew 320 basis points to exceed 90%, year-over-year.
Investment Activity
Ventas closed $1.2 billion of senior housing investments in the third quarter, and year to date has closed $5.2 billion of investments focused on senior housing. The Company expects these investments to increase its growth rate on a multiyear basis and generate attractive financial returns. The Company’s relationship-based investment momentum continues with a robust investment pipeline that is active and actionable.
Financial Strength and Flexibility
The Company’s Net Debt-to-Further Adjusted EBITDA* strengthened to 4.4x as of the end of the third quarter, representing a continued trend of sequential improvement and nearly a full turn improvement from the prior year period. The improvement was driven by SHOP NOI growth and equity-funded senior housing investments.
As of September 30, 2026, the Company had $4.5 billion in liquidity, supporting Ventas’s growth and financial flexibility. Liquidity includes availability under its unsecured credit facilities, cash and cash equivalents and unsettled equity forward sales agreements outstanding.
Increased Full Year 2026 Guidance
The Company is increasing its guidance for the full year. The Company’s 2026 guidance contains forward-looking statements and is based on a number of assumptions, including those identified later in this press release; actual results may differ materially. Ventas expects to report 2026 per share Attributable Net Income, Nareit FFO and Normalized FFO within the following ranges:
|
| As of 10/27/26 |
| As of 7/29/26 |
Attributable Net Income Per Share Range |
| $0.64 - $0.67 |
| $0.58 - $0.63 |
Attributable Net Income Per Share Midpoint |
| $0.66 |
| $0.61 |
Nareit FFO Per Share Range* |
| $3.83 - $3.86 |
| $3.76 - $3.81 |
Nareit FFO Per Share Midpoint* |
| $3.85 |
| $3.79 |
Normalized FFO Per Share Range* |
| $3.87 - $3.90 |
| $3.85 - $3.90 |
Normalized FFO Per Share Midpoint* |
| $3.89 |
| $3.88 |
Full Year 2026 Guidance Commentary Update
The increase in the Company’s guidance is primarily the result of 2026 accretive senior housing investment activity, partially offset by the impacts of interest rates and foreign exchange. Certain additional assumptions are set forth in the appendix.
Investor Presentation
An Earnings Presentation is posted to the Events & Presentations section of Ventas’s website at ir.ventasreit.com/events-and-presentations. Additional information regarding the Company can be found in its Supplemental posted at ir.ventasreit.com. The information contained on, or that may be accessed through, the Company’s website, including the information contained in the aforementioned Earnings Presentation and Supplemental, is not incorporated by reference into, and is not part of, this document.
Third Quarter 2026 Results Conference Call
Ventas will hold a conference call to discuss this earnings release on Wednesday, October 28, 2026 at 10:00 a.m. Eastern Time (9:00 a.m. Central Time).
The dial-in number for the conference call is (833) 461-5787 (or +1 (585) 542-9983 for international callers), and the participant passcode is 771494992. A live webcast can be accessed from the Investor Relations section of www.ventasreit.com.
A telephonic replay will be available at (833) 309-1852 (or +1 (929) 828-5978 for international callers), passcode 771494992, after the earnings call and will remain available for 30 days. The webcast replay will be posted in the Investor Relations section of www.ventasreit.com.
About Ventas
Ventas, Inc. (NYSE: VTR) is an S&P 500 company enabling exceptional environments that benefit a large and growing aging population. With approximately 1,500 properties in North America and the United Kingdom, Ventas occupies an essential role in the longevity economy. The Company’s growth is fueled by its approximately 1,000 senior housing communities, which provide valuable services to residents and enable them to thrive in supported environments. Ventas aims to deliver outsized performance by leveraging its operational expertise, data-driven insights from its Ventas OITM platform, extensive relationships and strong financial position. The Ventas portfolio also includes outpatient medical buildings, research centers and healthcare facilities. Ventas’s seasoned team of talented professionals shares a commitment to excellence, integrity and a common purpose of helping people live longer, healthier, happier lives.
Non-GAAP Financial Measures
This press release of Ventas, Inc. (the “Company,” “we,” “us,” “our” and similar terms) includes certain financial performance measures not defined by generally accepted accounting principles in the United States (“GAAP”), such as Nareit FFO, Normalized FFO, Net Operating Income (“NOI”), Cash NOI, Same-Store Cash NOI, Same-Store Cash NOI Margin, Same-Store Cash NOI Growth, Cash Operating Revenue, Same-Store Cash Operating Revenue and Net Debt to Further Adjusted EBITDA. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures are included in the appendix to this press release. Our definitions and calculations of these non-GAAP measures may not be the same as similar measures reported by other REITs.
These non-GAAP financial measures should not be considered as alternatives for, or superior to, financial measures calculated in accordance with GAAP.
Cautionary Statements
Certain of the information contained herein, including intra-quarter operating information, has been provided by our operators and we have not verified this information through an independent investigation or otherwise. We have no reason to believe that this information is inaccurate in any material respect, but we cannot assure you of its accuracy.
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among others, statements of expectations, beliefs, future plans and strategies, anticipated results from operations and developments and other matters that are not historical facts. Forward-looking statements include, among other things, statements regarding our and our officers’ intent, belief or expectation as identified by the use of phrases or words such as “assume,” “may,” “will,” “project,” “expect,” “believe,” “intend,” “anticipate,” “seek,” “target,” “forecast,” “plan,” “line-of-sight,” “outlook,” “potential,” “opportunity,” “estimate,” “could,” “would,” “should” and other comparable and derivative terms or the negatives thereof.
Forward-looking statements are based on management’s beliefs as well as on a number of assumptions concerning future events. You should not put undue reliance on these forward-looking statements, which are not a guarantee of performance and are subject to a number of uncertainties and other factors that could cause actual events or results to differ materially from those expressed or implied by the forward-looking statements. We do not undertake a duty to update these forward-looking statements, which speak only as of the date on which they are made. We urge you to carefully review the disclosures we make concerning risks and uncertainties that may affect our business and future financial performance, including those made below and in our filings with the Securities and Exchange Commission, such as in the sections titled “Cautionary Statements — Summary Risk Factors” and “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our subsequent Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K as we file them with the Securities and Exchange Commission.
Certain factors that could affect our future results and our ability to achieve our stated goals include, but are not limited to: (a) our exposure and the exposure of our managers, tenants and borrowers to complex and evolving governmental policy, laws and regulations, including relating to healthcare, data privacy, cybersecurity, artificial intelligence, international trade and environmental matters, the impact of such policies, laws and regulations on our and our managers’, tenants’ and borrowers’ business and the challenges and expense associated with complying with such policies, laws and regulations; (b) the impact of market, macroeconomic and general economic conditions on us, our managers, tenants and borrowers and in areas in which our properties are geographically concentrated, including changes in or elevated inflation, interest rates and exchange rates, labor market dynamics and rises in unemployment, tightening of lending standards and reduced availability of credit or capital, events that affect consumer confidence, and the actual and perceived state of the real estate markets and public and private capital markets; (c) our ability, and the ability of our managers, tenants and borrowers, to navigate the trends impacting our or their businesses and the industries in which we or they operate, including their ability to respond to the impact of the U.S. political environment on government funding and reimbursement programs, and the financial condition or business prospect of our managers, tenants and borrowers; (d) our ability to achieve the anticipated benefits and synergies from, and effectively integrate, our completed or anticipated acquisitions and investments; (e) our ability to identify and consummate future investments in healthcare assets and effectively manage our portfolio opportunities and our investments in co-investment vehicles, joint ventures and minority interests; (f) the potential for significant general and commercial claims, legal actions, investigations, regulatory proceedings and enforcement actions that could subject us or our managers, tenants or borrowers to increased operating costs, uninsured liabilities, including fines and other penalties, reputational harm or significant operational limitations, including the loss or suspension of or moratoriums on accreditations, licenses or certificates of need, suspension of or nonpayment for new admissions, denial of reimbursement, suspension, decertification or exclusion from federal, state or foreign healthcare programs or the closure of facilities or communities; (g) our reliance on third-party managers and tenants to operate or exert substantial control over properties they manage for, or lease from, us, which limits our control and influence over such properties, their operations and their performance; (h) our reliance and the reliance of our managers, tenants and borrowers on the financial, credit and capital markets and the risk that those markets may be disrupted or become constrained; (i) the risk of bankruptcy, inability to obtain benefits from governmental programs, insolvency or financial deterioration of our managers, tenants, borrowers and other obligors which may, among other things, have an adverse impact on the ability of such parties to make payments or meet their other obligations to us; (j) our dependency on a limited number of managers and tenants for a significant portion of our revenues and operating income; (k) our exposure to various operational risks, liabilities and claims from our operating assets; (l) our exposure to particular risks due to our specific asset classes and operating markets, such as adverse changes affecting our specific asset classes and the healthcare real estate sector, the competitiveness or financial viability of hospitals on or near the campuses where our outpatient medical buildings are located, our relationships with universities, the level of expense and uncertainty of our research tenants, and the limitation of our uses of some properties we own that are subject to ground lease, air rights or other restrictive agreements; (m) our ownership of properties or operation of business outside of the U.S. that may subject us to different or greater risks than those associated with our domestic operations; (n) the risk that our management agreements or leases are not renewed or are renewed on less favorable terms, that our managers or tenants default under those agreements or that we are unable to replace managers or tenants on a timely basis or on favorable terms, if at all; (o) the risk that the borrowers under our loans or other investments default or that, to the extent we are able to foreclose or otherwise acquire the collateral securing our loans or other investments, we will be required to incur additional expense or indebtedness in connection therewith, that the assets will underperform expectations or that we may not be able to subsequently dispose of all or part of such assets on favorable terms; (p) risks related to the recognition of reserves, allowances, credit losses or impairment charges which are inherently uncertain and may increase or decrease in the future and may not represent or reflect the ultimate value of, or loss that we ultimately realize with respect to, the relevant assets; (q) the risk of exposure to unknown liabilities from our investments in properties or businesses; (r) the impact of merger, acquisition and investment activity in the healthcare industry or otherwise affecting our managers, tenants or borrowers; (s) risks related to development, redevelopment and construction projects, including costs associated with inflation, rising or elevated interest rates, labor conditions and supply chain pressures, and risks related to increased construction and development in markets in which our properties are located, including adverse effect on our future occupancy rates; (t) our current and future amount of outstanding indebtedness, and our ability to access capital and to incur additional debt which is subject to our compliance with covenants in instruments governing our and our subsidiaries’ existing indebtedness; (u) increases in our borrowing costs as a result of becoming more leveraged, including in connection with acquisitions or other investment activity and rising or elevated interest rates; (v) the risk of potential dilution resulting from future sales or issuances of our equity securities; (w) the availability, adequacy and pricing of insurance coverage provided by our policies and policies maintained by our managers, tenants, borrowers or other counterparties; (x) the risks or uncertainties relating to the use of, or inability to take advantage of, the benefits of artificial intelligence by us or our managers, tenants or borrowers; (y) the occurrence of cybersecurity threats and incidents that could disrupt our or our managers’, tenants’ or borrower’s operations, result in the loss of confidential or personal information or damage our business relationships and reputation; (z) the risk of catastrophic or extreme weather and other natural events; (aa) our ability to attract and retain talented employees; (bb) our ability to maintain a positive reputation for quality and service with our key stakeholders; (cc) the limitations and significant requirements imposed upon our business as a result of our status as a REIT and the adverse consequences (including the possible loss of our status as a REIT) that would result if we are not able to comply with such requirements; (dd) the ownership limits contained in our certificate of incorporation with respect to our capital stock in order to preserve our qualification as a REIT, which may delay, defer or prevent a change of control of our company; (ee) risks and uncertainties related to the UPREIT Reorganization; and (ff) the other factors set forth in our periodic filings with the Securities and Exchange Commission.
CONSOLIDATED BALANCE SHEETS | |||||||
(In thousands, except per share amounts; dollars in USD; unaudited) | |||||||
|
|
|
| ||||
| As of September 30, 2026 |
| As of December 31, 2025 | ||||
Assets |
|
|
| ||||
Real estate investments: |
|
|
| ||||
Land and improvements | $ | 3,390,024 |
|
| $ | 2,962,738 |
|
Buildings and improvements |
| 34,209,438 |
|
|
| 30,872,598 |
|
Construction in progress |
| 248,737 |
|
|
| 358,811 |
|
Acquired lease intangibles |
| 2,046,823 |
|
|
| 1,680,567 |
|
Operating lease assets |
| 314,623 |
|
|
| 295,838 |
|
|
| 40,209,645 |
|
|
| 36,170,552 |
|
Accumulated depreciation and amortization |
| (12,912,169 | ) |
|
| (12,043,619 | ) |
Net real estate property |
| 27,297,476 |
|
|
| 24,126,933 |
|
Secured loans receivable and investments, net |
| 442,287 |
|
|
| 143,913 |
|
Investments in unconsolidated real estate entities |
| 584,905 |
|
|
| 617,571 |
|
Net real estate investments |
| 28,324,668 |
|
|
| 24,888,417 |
|
Cash and cash equivalents |
| 202,009 |
|
|
| 741,067 |
|
Escrow deposits and restricted cash |
| 27,623 |
|
|
| 45,070 |
|
Goodwill |
| 1,045,824 |
|
|
| 1,046,072 |
|
Assets held for sale |
| 100,813 |
|
|
| 42,993 |
|
Deferred income tax assets, net |
| 2,807 |
|
|
| 2,797 |
|
Other assets |
| 921,638 |
|
|
| 825,529 |
|
Total assets | $ | 30,625,382 |
|
| $ | 27,591,945 |
|
Liabilities and equity |
|
|
| ||||
Liabilities: |
|
|
| ||||
Senior notes payable and other debt | $ | 12,436,652 |
|
| $ | 13,011,016 |
|
Accrued interest payable |
| 97,664 |
|
|
| 143,104 |
|
Operating lease liabilities |
| 230,568 |
|
|
| 208,602 |
|
Accounts payable and other liabilities |
| 1,469,788 |
|
|
| 1,240,820 |
|
Liabilities related to assets held for sale |
| 6,489 |
|
|
| 4,032 |
|
Deferred income tax liabilities |
| 31,801 |
|
|
| 23,409 |
|
Total liabilities |
| 14,272,962 |
|
|
| 14,630,983 |
|
Redeemable OP unitholder and noncontrolling interests |
| 492,756 |
|
|
| 375,154 |
|
Commitments and contingencies |
|
|
| ||||
Equity: |
|
|
| ||||
Ventas stockholders’ equity: |
|
|
| ||||
Preferred stock, $1.00 par value; 10,000 shares authorized, unissued |
| — |
|
|
| — |
|
Common stock, $0.25 par value; 1,200,000 shares authorized, 528,820 and 474,926 shares outstanding at September 30, 2026 and December 31, 2025, respectively |
| 132,205 |
|
|
| 118,732 |
|
Capital in excess of par value |
| 23,834,762 |
|
|
| 19,976,183 |
|
Accumulated other comprehensive loss |
| (23,689 | ) |
|
| (39,851 | ) |
Retained earnings (deficit) |
| (8,136,215 | ) |
|
| (7,527,777 | ) |
Treasury stock, 0 shares issued |
| — |
|
|
| (34 | ) |
Total Ventas stockholders’ equity |
| 15,807,063 |
|
|
| 12,527,253 |
|
Noncontrolling interests |
| 52,601 |
|
|
| 58,555 |
|
Total equity |
| 15,859,664 |
|
|
| 12,585,808 |
|
Total liabilities and equity | $ | 30,625,382 |
|
| $ | 27,591,945 |
|
CONSOLIDATED STATEMENTS OF INCOME | |||||||||||||||
(In thousands, except per share amounts; dollars in USD; unaudited) | |||||||||||||||
|
|
|
|
|
|
|
| ||||||||
| For the Three Months Ended September 30, |
| For the Nine Months Ended September 30, | ||||||||||||
|
| 2026 |
|
|
| 2025 |
|
|
| 2026 |
|
|
| 2025 |
|
Revenues |
|
|
|
|
|
|
| ||||||||
Rental income: |
|
|
|
|
|
|
| ||||||||
Triple-net leased properties | $ | 129,484 |
|
| $ | 160,050 |
| $ | 377,411 |
|
| $ | 468,865 | ||
Outpatient medical and research portfolio |
| 233,239 |
|
|
| 226,200 |
|
|
| 691,948 |
|
|
| 668,333 |
|
|
| 362,723 |
|
|
| 386,250 |
|
|
| 1,069,359 |
|
|
| 1,137,198 |
|
Resident fees and services |
| 1,450,802 |
|
|
| 1,088,546 |
|
|
| 4,107,090 |
|
|
| 3,090,164 |
|
Third-party capital management revenues |
| 4,140 |
|
|
| 4,492 |
|
|
| 12,796 |
|
|
| 13,225 |
|
Income from loans and investments |
| 12,165 |
|
|
| 5,524 |
|
|
| 22,866 |
|
|
| 14,243 |
|
Interest and other income |
| 1,961 |
|
|
| 4,184 |
|
|
| 6,238 |
|
|
| 13,133 |
|
Total revenues |
| 1,831,791 |
|
|
| 1,488,996 |
|
|
| 5,218,349 |
|
|
| 4,267,963 |
|
Expenses |
|
|
|
|
|
|
| ||||||||
Interest |
| 161,388 |
|
|
| 158,124 |
|
|
| 477,564 |
|
|
| 457,778 |
|
Depreciation and amortization |
| 446,013 |
|
|
| 357,173 |
|
|
| 1,236,192 |
|
|
| 1,026,417 |
|
Property-level operating expenses: |
|
|
|
|
|
|
| ||||||||
Senior housing |
| 1,020,832 |
|
|
| 786,250 |
|
|
| 2,899,163 |
|
|
| 2,236,952 |
|
Outpatient medical and research portfolio |
| 80,529 |
|
|
| 79,136 |
|
|
| 238,611 |
|
|
| 230,094 |
|
Triple-net leased properties |
| 3,201 |
|
|
| 3,012 |
|
|
| 9,244 |
|
|
| 10,505 |
|
|
| 1,104,562 |
|
|
| 868,398 |
|
|
| 3,147,018 |
|
|
| 2,477,551 |
|
Third-party capital management expenses |
| 1,794 |
|
|
| 1,517 |
|
|
| 5,333 |
|
|
| 4,969 |
|
General, administrative and professional fees |
| 47,698 |
|
|
| 40,387 |
|
|
| 157,430 |
|
|
| 136,392 |
|
Loss on extinguishment of debt, net |
| 14 |
|
|
| 119 |
|
|
| 546 |
|
|
| 119 |
|
Transaction, transition and restructuring costs |
| 7,872 |
|
|
| 5,472 |
|
|
| 28,009 |
|
|
| 16,081 |
|
Other expense |
| 9,821 |
|
|
| 13,370 |
|
|
| 23,975 |
|
|
| 20,621 |
|
Total expenses |
| 1,779,162 |
|
|
| 1,444,560 |
|
|
| 5,076,067 |
|
|
| 4,139,928 |
|
Income before unconsolidated entities, real estate dispositions, income taxes and noncontrolling interests |
| 52,629 |
|
|
| 44,436 |
|
|
| 142,282 |
|
|
| 128,035 |
|
(Loss) income from unconsolidated entities |
| (5,464 | ) |
|
| 16,644 |
|
|
| (20,626 | ) |
|
| 12,195 |
|
Gain on real estate dispositions |
| 815 |
|
|
| 1,283 |
|
|
| 16,037 |
|
|
| 35,268 |
|
Income tax benefit |
| 19,301 |
|
|
| 6,345 |
|
|
| 60,856 |
|
|
| 13,028 |
|
Net income |
| 67,281 |
|
|
| 68,708 |
|
|
| 198,549 |
|
|
| 188,526 |
|
Net income attributable to noncontrolling interests |
| 1,901 |
|
|
| 2,661 |
|
|
| 6,687 |
|
|
| 7,347 |
|
Net income attributable to common stockholders | $ | 65,380 |
|
| $ | 66,047 |
|
| $ | 191,862 |
|
| $ | 181,179 |
|
Earnings per common share |
|
|
|
|
|
|
| ||||||||
Basic: |
|
|
|
|
|
|
| ||||||||
Net income | $ | 0.13 |
|
| $ | 0.15 |
|
| $ | 0.40 |
|
| $ | 0.42 |
|
Net income attributable to common stockholders |
| 0.13 |
|
|
| 0.14 |
|
|
| 0.39 |
|
|
| 0.40 |
|
Diluted: |
|
|
|
|
|
|
| ||||||||
Net income | $ | 0.13 |
|
| $ | 0.15 |
|
| $ | 0.40 |
|
| $ | 0.41 |
|
Net income attributable to common stockholders |
| 0.13 |
|
|
| 0.14 |
|
|
| 0.38 |
|
|
| 0.40 |
|
Weighted average shares used in computing earnings per common share |
|
|
|
|
|
|
| ||||||||
Basic |
| 513,946 |
|
|
| 456,032 |
|
|
| 493,324 |
|
|
| 449,572 |
|
Diluted |
| 518,937 |
|
|
| 463,415 |
|
|
| 501,284 |
|
|
| 456,392 |
|
BJ Grant
(877) 4-VENTAS
| Oct-28 | |
| Oct-28 | |
| Oct-27 | |
| Sep-25 | |
| Sep-15 | |
| Sep-14 | |
| Aug-17 | |
| Aug-11 | |
| Aug-11 | |
| Jul-30 | |
| Jul-29 | |
| Jul-29 | |
| Jun-29 | |
| Jun-22 | |
| Jun-03 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite